Journal article
Health- and Vision-Related Quality of Life in a Randomized Controlled Trial Comparing Methotrexate and Mycophenolate Mofetil for Uveitis
Nicole K Kelly, Aheli Chattopadhyay, SR Rathinam, John A Gonzales, Radhika Thundikandy, Anuradha Kanakath, S Bala Murugan, R Vedhanayaki, Dean Cugley, Lyndell L Lim, Eric B Suhler, Hassan A Al-Dhibi, Caleb D Ebert, Elyse J Berlinberg, Travis C Porco, Nisha R Acharya
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2021
Abstract
PURPOSE: To evaluate changes in health-related and vision-related quality of life (VRQoL) among patients with noninfectious uveitis who were treated with antimetabolites. DESIGN: Secondary analysis of a randomized controlled trial. PARTICIPANTS: Patients with noninfectious uveitis from India, the United States, Australia, Saudi Arabia, and Mexico. METHODS: From 2013 through 2017, 216 participants were randomized to receive 25 mg weekly oral methotrexate or 1.5 g twice daily oral mycophenolate mofetil. Median changes in quality of life (QoL) were measured using Wilcoxon signed-rank tests, and differences between treatment groups were measured using linear mixed models, adjusting for baseline ..
View full abstractGrants
Awarded by National Eye Institute, National Institutes of Health, Bethesda, Maryland
Funding Acknowledgements
Supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant nos.: U10 EY021125 and EY06190); Research to Prevent Blindness, Inc., New York, New York (unrestricted grant to the Department of Ophthalmology at UCSF); and That Man May See Foundation. The sponsors had no role in the design or conduct of this research.